Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and m...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2018-11-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/9547 |
| _version_ | 1826588026365542400 |
|---|---|
| author | Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto |
| author_facet | Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto |
| author_sort | Anna A. Mosikian |
| collection | DOAJ |
| description | Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and metabolic predictors of better hypoglycemic response to evogliptin. Matherials and methods: We have conducted a retrospective study, based on the data of a randomized clinical trial comparing effectiveness and safety of evogliptin and sitagliptin in Russian and Korean subpopulations. We provide univariate linear regression models for separate subpopulations and a multivariate stepwise regression model for the combined subpopulation. HbA1c change after 24 weeks of evogliptin treatment was a primary endpoint and a dependent variable in the analysis. Results: The decrease of HbA1c after 24 weeks of treatment with evogliptin in Russian subpopulation negatively correlates with triglycerides/HDL level (p = 0,046). In South Korean subpopulation it correlates positively with HbA1c level at baseline (p < 0,0001). In order to increase the statistical power of the analysis the data of both populations were combined. According to the combined data, the decrease of HbA1c after 24 weeks of treatment with evogliptin positively correlates with HbA1c level at baseline (p<0.0001) and log(HOMA-B) (p=0.0042), and it negatively correlates with log(triglycerides/HDL) (p=0.0057), blood phosphorous concentration (p=0.014) and statin treatment (p=0.044). No correlation of HbA1c change at week 24 was observed with body mass index, diabetes duration and blood C-peptide concentration. Patients able to achieve HbA1c<7,0 % had higher HOMA-B (53.22 ± 36.95 и 39.67 ± 24.74, respectively, р=0.033) and were tend to have higher HDL concentration (1.36 ± 0.28 и 1.26 ± 0.26 mmol/l, respectively, р=0.076) and lower triglycerides to HDL ratio (0.87 ± 0.70 и 1.48 ± 0.95, respectively, р=0.079). Conclusion: A patient, who benefits more when treated with evogliptin, has higher HOMA-B, lower triglycerides to HDL ratio and phosphorous concentration in the 1-2 quartiles of the normal range. Triglycerides to HDL ratio is, probably, a specific effectiveness predictor for Russian, but not for Korean subpopulation. These data prove the difference in effectiveness prediction for different drugs of DPP-4 inhibitors group and reveal the need of further investigation. |
| first_indexed | 2024-03-08T15:19:52Z |
| format | Article |
| id | doaj.art-0cda49c2db13461287d49fbf760d288a |
| institution | Directory Open Access Journal |
| issn | 2072-0351 2072-0378 |
| language | English |
| last_indexed | 2025-03-14T16:34:47Z |
| publishDate | 2018-11-01 |
| publisher | Endocrinology Research Centre |
| record_format | Article |
| series | Сахарный диабет |
| spelling | doaj.art-0cda49c2db13461287d49fbf760d288a2025-02-21T09:29:35ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782018-11-0121533334310.14341/DM95478588Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean populationAnna A. Mosikian0Alina Y. Babenko1Yulia A. Sevastyanova2Roman V. Drai3Evgenij V. Shlyakhto4<p>National Almazov North-West Medical Research Centre</p><p>National Almazov North-West Medical Research Centre</p><p>Geropharm, Pharmaceutical Company</p><p>Geropharm, Pharmaceutical Company</p><p>National Almazov North-West Medical Research Centre</p>Background: Individualized treatment has already become a part of a routine clinical care. Many data on the effectiveness prediction of commercially available DPP-4 inhibitors had been published, but not on the effectiveness prediction of evogliptin. Aim: To reveal the clinical characteristics and metabolic predictors of better hypoglycemic response to evogliptin. Matherials and methods: We have conducted a retrospective study, based on the data of a randomized clinical trial comparing effectiveness and safety of evogliptin and sitagliptin in Russian and Korean subpopulations. We provide univariate linear regression models for separate subpopulations and a multivariate stepwise regression model for the combined subpopulation. HbA1c change after 24 weeks of evogliptin treatment was a primary endpoint and a dependent variable in the analysis. Results: The decrease of HbA1c after 24 weeks of treatment with evogliptin in Russian subpopulation negatively correlates with triglycerides/HDL level (p = 0,046). In South Korean subpopulation it correlates positively with HbA1c level at baseline (p < 0,0001). In order to increase the statistical power of the analysis the data of both populations were combined. According to the combined data, the decrease of HbA1c after 24 weeks of treatment with evogliptin positively correlates with HbA1c level at baseline (p<0.0001) and log(HOMA-B) (p=0.0042), and it negatively correlates with log(triglycerides/HDL) (p=0.0057), blood phosphorous concentration (p=0.014) and statin treatment (p=0.044). No correlation of HbA1c change at week 24 was observed with body mass index, diabetes duration and blood C-peptide concentration. Patients able to achieve HbA1c<7,0 % had higher HOMA-B (53.22 ± 36.95 и 39.67 ± 24.74, respectively, р=0.033) and were tend to have higher HDL concentration (1.36 ± 0.28 и 1.26 ± 0.26 mmol/l, respectively, р=0.076) and lower triglycerides to HDL ratio (0.87 ± 0.70 и 1.48 ± 0.95, respectively, р=0.079). Conclusion: A patient, who benefits more when treated with evogliptin, has higher HOMA-B, lower triglycerides to HDL ratio and phosphorous concentration in the 1-2 quartiles of the normal range. Triglycerides to HDL ratio is, probably, a specific effectiveness predictor for Russian, but not for Korean subpopulation. These data prove the difference in effectiveness prediction for different drugs of DPP-4 inhibitors group and reveal the need of further investigation.https://www.dia-endojournals.ru/jour/article/view/9547diabetes mellituspersonalized medicinedpp-4 inhibitorsefficacy predictionevogliptin |
| spellingShingle | Anna A. Mosikian Alina Y. Babenko Yulia A. Sevastyanova Roman V. Drai Evgenij V. Shlyakhto Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population Сахарный диабет diabetes mellitus personalized medicine dpp-4 inhibitors efficacy prediction evogliptin |
| title | Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population |
| title_full | Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population |
| title_fullStr | Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population |
| title_full_unstemmed | Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population |
| title_short | Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population |
| title_sort | effectiveness prediction of evogliptin treatment in type 2 diabetes mellitus in russian korean population |
| topic | diabetes mellitus personalized medicine dpp-4 inhibitors efficacy prediction evogliptin |
| url | https://www.dia-endojournals.ru/jour/article/view/9547 |
| work_keys_str_mv | AT annaamosikian effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT alinaybabenko effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT yuliaasevastyanova effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT romanvdrai effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation AT evgenijvshlyakhto effectivenesspredictionofevogliptintreatmentintype2diabetesmellitusinrussiankoreanpopulation |